Technology evaluation: cantuzumab mertansine, ImmunoGen.
ImmunoGen is developing cantuzumab mertansine, in which the CanAg antigen-targeted humanized antibody C242 is conjugated to the company's proprietary cytotoxic agent, DM1, using ImmunoGen's tumor-activated prodrug technology. Cantuzumab mertansine is undergoing phase II trials for the potential treatment of CanAg-expressing cancers, including pancreatic and colorectal cancers and non-small-cell lung cancer.
Smith
Suzanne V
SV
Australian Nuclear Science and Technology Organisation, Materials Engineering and Science, Menai, NSW 2234. svs@ansto.gov.au
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004341:Drug Evaluation / Q000379:methods; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods*
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D008453:Maytansine; C483240:cantuzumab mertansine